| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Miriam Kessi, Yulin Tang, Baiyu Chen, Guoli Wang, Ciliu Zhang, Fang He, Jing Peng, Fei Yin, Lifen Yan. Pediatric Ocular Myasthenia Gravis: Single-Center Experience. Pediatric neurology. vol 153. 2024-02-21. PMID:38382246. |
currently, there is no universally accepted standard treatment for ocular myasthenia gravis (omg) in children. |
2024-02-21 |
2024-02-24 |
Not clear |
| J McCallion, A Borsi, W Noel, J Lee, W Karmous, S Sattler, G M Boggia, E J Hardy, C R Mitchell, S A Mitchell, Nils Erik Gilhu. Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa. BMC neurology. vol 24. issue 1. 2024-02-09. PMID:38336636. |
myasthenia gravis (mg) is a rare autoimmune disease characterised by muscle weakness, and progression from ocular (omg) to generalised (gmg) symptoms results in a substantial negative impact on quality of life (qol). |
2024-02-09 |
2024-02-12 |
Not clear |
| Minghua Shi, Zhuneng Lu, Aijiao Qin, Jing Cheng, Simin Chen, Yiqiao Xin. A controlled clinical study on efficacy and safety of periocular triamcinolone acetonide injection for treating ocular myasthenia gravis. BMC ophthalmology. vol 24. issue 1. 2024-01-23. PMID:38254041. |
to evaluate the efficacy and safety of peribulbar triamcinolone acetonide injection for treating ocular myasthenia gravis (omg), with a comparison of traditional oral drug therapy. |
2024-01-23 |
2024-01-25 |
Not clear |
| Kai-Yue Zhang, Wei-Wei Duan, Yue-Bei Luo, Yi Li, Jue Hu, Huan Yan. Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study. Orphanet journal of rare diseases. vol 19. issue 1. 2024-01-19. PMID:38243274. |
oral prednisone has been recognized as the first-line therapy for the treatment of ocular myasthenia gravis (omg). |
2024-01-19 |
2024-01-22 |
Not clear |
| Laura Wilson, Helen Davi. The Role of Thymoma and Thymic Hyperplasia as Prognostic Risk Factors for Secondary Generalisation in Adults with Ocular Myasthenia Gravis: A Systematic Narrative Review. The British and Irish orthoptic journal. vol 19. issue 1. 2023-12-04. PMID:38046270. |
the conversion of ocular myasthenia gravis (omg) to generalised myasthenia gravis (gmg) is reported to differ depending on the presence of generalisation risk factors (mazzoli et al. |
2023-12-04 |
2023-12-10 |
Not clear |
| Yajun Mu, Xin Huang, Yuanting Yang, Ziqing Huang, Jiaxin Chen, Shiyin Li, Yuying Dong, Fangyuan Chen, Rijia Zhang, Jian Chen, Huiyu Feng, Qing Zho. Study of serum exosome miRNA as a biomarker for early onset adult ouclar myasthenia gravis. Gene. 2023-11-28. PMID:38013129. |
by extracting and sequencing mirnas from serum exosomes of patients with early-onset ocular myasthenia gravis (omg), generalized myasthenia gravis (gmg) and healthy controls, we screened differentially expressed mirnas and explored the possibility as potential biomarkers for early-onset omg. |
2023-11-28 |
2023-11-29 |
Not clear |
| Kenshiro Fuse, Amane Araki, Saori Morozumi, Keizo Yasui, Tomoyuki Kazuta, Seiya Noda, Masahisa Katsun. [A case of anti-acetylcholine receptor antibody-positive ocular myasthenia gravis with anti-titin antibody and anti-Kv1.4 antibody positive inflammatory myopathy]. Rinsho shinkeigaku = Clinical neurology. 2023-11-21. PMID:37989286. |
an 84-year-old man was diagnosed with anti-acetylcholine receptor (achr) antibody-positive ocular myasthenia gravis (omg) at the age of 77 and received treatment. |
2023-11-21 |
2023-11-29 |
Not clear |
| Rui-Yan Wang, Hui Chen, Zhi-Xin Huang, Yong Chen, Jian-Min Zhon. [Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis: a retrospective analysis]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics. vol 25. issue 10. 2023-10-31. PMID:37905760. |
to investigate the clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis (omg). |
2023-10-31 |
2023-11-08 |
Not clear |
| Jingsi Wang, Hongyu Zhou, Hongxi Chen, Huiyu Feng, Ting Chang, Chao Sun, Rongjing Guo, Zhe Ruan, Fangfang Bi, Jing Li, Jianwen Wang, Kang Wang, Gaoting Ma, Shaoyuan Lei, Chunxiu Wang, Zhihong Wang, Feifei Huang, Shu Zhang, Qi Wen, Yaye Wang, Yanan Sun, Yun Li, Nairong Xie, Haoran Liu, Yuting Jiang, Lin Lei, Zhirong Fan, Shengyao Su, Yan Lu, Li Di, Min Xu, Min Wang, Hai Chen, Suobin Wang, Xinmei Wen, Wenjia Zhu, Jianying Duo, Yue Huang, Deqiang Zheng, Yuwei D. Environmental factors affecting the risk of generalization for ocular-onset myasthenia gravis: a nationwide cohort study. QJM : monthly journal of the Association of Physicians. 2023-10-06. PMID:37802883. |
the environmental effects on the prognosis of ocular myasthenia gravis (omg) remain largely unexplored. |
2023-10-06 |
2023-10-15 |
Not clear |
| Wu Yunqing, Cui Shilei, Li Yong, Li Qing, Shi Xiaohong, Wang Jiawe. Cavernous Sinus MRI Findings in Inflammatory and Ischemic Oculomotor Cranial Nerve Palsies. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2023-09-26. PMID:37751328. |
this study explored the cavernous sinus mri findings for cavernous sinus idiopathic inflammation (inflammation group), microvascular ischemic ocn palsy (ischemic group), and ocular myasthenia gravis (omg group) patients. |
2023-09-26 |
2023-10-07 |
Not clear |
| Neşe Çelebisoy, Asim Orujov, Fidan Balayeva, Hüseyin Nezih Özdemir, Ayşın Kısabay Ak, Figen Gökça. Prognostic predictors of remission in ocular myasthenia gravis. Acta neurologica Belgica. vol 123. issue 5. 2023-09-16. PMID:36474006. |
ocular myasthenia gravis (omg) constitutes 15% of all myasthenia gravis patients. |
2023-09-16 |
2023-10-07 |
Not clear |
| Clarissa Ern Hui Fang, Desta Bokre, Sui H Won. Clinical Characteristics Associated With Secondary Generalization in Ocular Myasthenia Gravis Patients: A Systematic Review and Meta-analysis. Neurology. 2023-08-29. PMID:37643888. |
ocular myasthenia gravis (omg) is an autoimmune disorder resulting in ocular symptoms such as diplopia and ptosis. |
2023-08-29 |
2023-09-07 |
Not clear |
| Mohamad Agha, Helen Ismail, Raja Sawaya, Johnny Salame. Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: A pilot clinical trial. Muscle & nerve. 2023-06-01. PMID:37259693. |
most patients with myasthenia gravis (mg) develop ocular manifestations during their illness and up to 22% may have isolated ocular myasthenia gravis (omg). |
2023-06-01 |
2023-08-14 |
Not clear |
| Tomoko Narita, Shunya Nakane, Akiko Nagaishi, Naoya Minami, Masaaki Niino, Naoki Kawaguchi, Hiroyuki Murai, Jun-Ichi Kira, Jun Shimizu, Kazuo Iwasa, Hiroaki Yoshikawa, Yuki Hatanaka, Masahiro Sonoo, Yuko Shimizu, Hidenori Matsu. Immunotherapy for ocular myasthenia gravis: an observational study in Japan. Therapeutic advances in neurological disorders. vol 16. 2023-04-13. PMID:37051222. |
treatment for ocular myasthenia gravis (omg) has not yet been well established. |
2023-04-13 |
2023-08-14 |
Not clear |
| Montana Supawongwattana, Kavin Vanikieti, Panitha Jindahra, Tanyatuth Padungkiatsagu. Significance of Acetylcholine Receptor Antibody Titers in Acetylcholine Receptor Antibody-Positive Ocular Myasthenia Gravis: Generalization and Presence of Thyroid Autoimmune Antibodies and Thymoma. Clinical ophthalmology (Auckland, N.Z.). vol 17. 2023-03-06. PMID:36875532. |
to evaluate the association in acetylcholine receptor (achr) antibody-positive ocular myasthenia gravis (omg) subjects between achr antibody titers and conversion to generalized myasthenia gravis (gmg), the presence of thyroid autoimmune antibodies, and the presence of thymoma. |
2023-03-06 |
2023-08-14 |
human |
| Parinee Kemchoknatee, Anyarak Armornpetchsathaporn, Duanghathai Tangon, Thansit Srisombu. Age of onset and factors affecting treatment responses in ocular myasthenia gravis. International ophthalmology. 2023-03-06. PMID:36879110. |
ocular myasthenia gravis (omg) is an autoimmune disease which causes ptosis, diplopia, or both. |
2023-03-06 |
2023-08-14 |
Not clear |
| Raed Behbehan. Ocular Myasthenia Gravis: A Current Overview. Eye and brain. vol 15. 2023-02-13. PMID:36778719. |
ocular myasthenia gravis (omg) is a neuromuscular disease characterized by autoantibody production against post-synaptic proteins in the neuromuscular junction. |
2023-02-13 |
2023-08-14 |
Not clear |
| Do-Hyung Kim, Hyeon Cheol Roh, Shin Yeop O. Ophthalmologic clinical features of ocular myasthenia gravis. Medicine. vol 102. issue 2. 2023-01-13. PMID:36637960. |
to investigate the clinical features of ocular myasthenia gravis (omg) in ophthalmology. |
2023-01-13 |
2023-08-14 |
Not clear |
| Zhuajin Bi, Yayun Cao, Mengcui Gui, Jing Lin, Qing Zhang, Yue Li, Suqiong Ji, Bitao B. Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2022-12-05. PMID:36469201. |
to explore the factors and risk mapping model of progression from ocular myasthenia gravis (omg) to generalized myasthenia gravis (gmg) in adult-onset patients. |
2022-12-05 |
2023-08-14 |
Not clear |
| Clarissa E H Fang, Desta Bokre, Sui H Won. Clinical characteristics of ocular myasthenia gravis and outcomes of secondary generalisation: a systematic review protocol. BMJ open. vol 12. issue 9. 2022-09-20. PMID:36127086. |
we aim to systematically assess the clinical characteristics of ocular myasthenia gravis (omg) and report on the proportion of patients who develop secondary generalised myasthenia gravis (sgmg). |
2022-09-20 |
2023-08-14 |
Not clear |